<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27818" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Propranolol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shahrokhi </surname>
            <given-names>Mahsa</given-names>
          </name>
          <aff>Saint James School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mahsa Shahrokhi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27818.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Propranolol can be used to ameliorate the sympathetic response in angina, tachyarrhythmias, prevention of acute ischemic attacks, migraine prophylaxis, and restless leg syndrome. Propranolol can be used in almost all cases if the desired result is to slow contractility and decrease a patient&#x02019;s heart rate. Propranolol is also used off-label in a variety of other cases, for instance, in performance anxiety, which is a subset of social phobia, a psychiatric condition whose symptoms also include tachycardia, sweating, and flushing secondary to the activation of the sympathetic nervous system. This activity examines the indications, dosing, contraindications, mechanism, and management of propranolol therapy by the interprofessional healthcare team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of propranolol.</p></list-item><list-item><p>Describe the possible adverse effects of propranolol.</p></list-item><list-item><p>Review the appropriate monitoring for patients taking propranolol.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance Propranolol and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27818&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27818">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27818.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Propranolol is a competitive beta-adrenergic receptor antagonist devoid of agonist activity, making it the&#x000a0;prototype for comparison to other beta-antagonists.<xref ref-type="bibr" rid="article-27818.r1">[1]</xref>&#x000a0;A British scientist, Sir James Black, first developed propranolol for the treatment of angina pectoris.&#x000a0;Over the following years, propranolol started to gain recognition in the treatment of a variety of cardiovascular and noncardiovascular disease processes, making it a widely used pharmaceutical drug.<xref ref-type="bibr" rid="article-27818.r2">[2]</xref>&#x000a0;</p>
        <p>B-adrenoreceptor antagonists, including propranolol, have been advised to be used for the treatment of heart failure, atrial fibrillation, and coronary artery disease. Furthermore, they have been demonstrated&#x000a0;to improve mortality and morbidity in those with hypertension complicated with heart failure, angina, or any history of previous myocardial infarctions.<xref ref-type="bibr" rid="article-27818.r3">[3]</xref>&#x000a0;Propranolol can also enhance&#x000a0;the sympathetic response in angina and tachyarrhythmias while also preventing acute ischemic attacks. It is also a critical drug used&#x000a0;in the treatment of hyperthyroid-induced thyrotoxicosis.<xref ref-type="bibr" rid="article-27818.r4">[4]</xref></p>
        <p>Propranolol not only has extensive use in cardiovascular disease, but it also has several implications in the treatment of noncardiovascular disease processes. It is used as a means of migraine prophylaxis, treatment of restless leg syndrome, essential tremors, and has even been of great success in treating infantile hemangioma.<xref ref-type="bibr" rid="article-27818.r5">[5]</xref>&#x000a0;</p>
        <p>Off-label use of propranolol includes performance anxiety, which is a subset of a social phobia presenting with tachycardia, sweating, and flushing that occurs secondary to increased activation of the sympathetic nervous system.<xref ref-type="bibr" rid="article-27818.r6">[6]</xref></p>
        <p>The extensive use of propranolol in the medical field highlights the vast importance of the discovery of the drug to society.&#x000a0;</p>
      </sec>
      <sec id="article-27818.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Propranolol is a&#x000a0;nonselective beta-adrenoreceptor antagonist, also classified as a class II antiarrhythmic. It exerts its response by competitively blocking beta-1 and beta-2 adrenergic stimulation in the heart, which is typically induced by epinephrine and norepinephrine.<xref ref-type="bibr" rid="article-27818.r7">[7]</xref></p>
        <p>Beta-1 receptors are present on cardiac myocytes, including the sinoatrial and atrioventricular nodes. When there is an activation of these receptors, there is an increase in cyclic AMP, which leads to increased intracellular calcium. This process leads to increased contractility of muscle fibers. When there is a blockage of beta-adrenergic receptors, this results in an overall decreased workload of the heart, which leads to subsequent reduced oxygen demand and myocardial remodeling.<xref ref-type="bibr" rid="article-27818.r8">[8]</xref></p>
        <p>Beta-2 receptor activation, on the other hand, leads to increased cyclic AMP that activates protein kinase A, leading to the relaxation of smooth muscle cells in a variety of organs and vessels. Therefore, when beta-2 receptors are blocked, this leads to a small amount of vasoconstriction. This effect can make the use of emergency epinephrine in asthmatics quite problematic, as it blocks the receptors that&#x000a0;epinephrine would potentially bind to in the lungs.<xref ref-type="bibr" rid="article-27818.r9">[9]</xref> Beta-blockers are highly protein-bound and are well distributed throughout the body with a Vd of about 4&#x000a0;to 6L/kg.<xref ref-type="bibr" rid="article-27818.r9">[9]</xref></p>
      </sec>
      <sec id="article-27818.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Like most medications, beta-blockers are metabolized predominately in the liver( both the active and inactive compounds). Approximately a quarter of the ingested drug reaches systemic circulation due to the first-pass metabolism in the hepatic circulation.<xref ref-type="bibr" rid="article-27818.r10">[10]</xref></p>
        <p>The active metabolite of propranolol is 4-hydroxypropranolol, which is formed through hydroxylation using the CYP2D6 enzyme.<xref ref-type="bibr" rid="article-27818.r11">[11]</xref></p>
        <p>Furthermore, like most ingested medications, propranolol is predominantly cleared by the renal system, with a half-life of about 3&#x000a0;to 6 hours in patients with healthy renal systems.<xref ref-type="bibr" rid="article-27818.r10">[10]</xref></p>
        <p>Propranolol administration can be either oral or intravenous. With intravenous administration, there should also be continuous electrocardiogram monitoring with a slow infusion. This route of administration primarily occurs in an inpatient setting.</p>
        <p>The doses of propranolol vary, being primarily dependent on what condition the medication is treating.<xref ref-type="bibr" rid="article-27818.r12">[12]</xref></p>
      </sec>
      <sec id="article-27818.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common side effects of using propranolol include bradycardia, gastrointestinal issues, abdominal pain, nausea, erectile dysfunction, and wheezing/bronchospasms.<xref ref-type="bibr" rid="article-27818.r13">[13]</xref>&#x000a0;Propranolol use can also cause drowsiness, fatigue, and cold extremities. Some extreme side effects to be aware of include allergic reactions, insulin resistance, and hallucinations. Prescribers need to explain and discuss all of the side effects before giving patients a prescription for propranolol.<xref ref-type="bibr" rid="article-27818.r13">[13]</xref></p>
      </sec>
      <sec id="article-27818.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Prescribers should exercise extreme caution when prescribing beta-blockers to patients with diabetes. This is because this class of medication can mask the symptoms of hypoglycemia, which includes flushing, tachycardia, sweating, and dizziness.<xref ref-type="bibr" rid="article-27818.r14">[14]</xref></p>
        <p>Furthermore, since the main effect of propranolol is to decrease heart rate, it is contraindicated in those who have bradycardia (less than 60 beats per minute).</p>
        <p>Propranolol is also contraindicated in those with any lung pathologies, such as COPD, asthma, or emphysema. The pathophysiology of this mechanism is solely due to the effects that beta-2 receptors have on lung function. Normally, activation of beta-2 receptors vasodilates the smooth muscle in the lungs. When using agents like propranolol in patients with underlying lung issues, the blockage of beta-2 causes vasoconstriction of smooth muscle, worsening respiratory function. Physicians should only prescribe selective beta-blockers in such patients; these drugs only block beta-1 receptors and spare beta-2 receptors.<xref ref-type="bibr" rid="article-27818.r15">[15]</xref></p>
        <p>During cocaine toxicity, prescribers should never use any beta-blocker with an unopposed alpha blockade since this can lead to massive unopposed alpha-adrenergic activity and lead to an enormous spike in blood pressure which may even result in death.<xref ref-type="bibr" rid="article-27818.r16">[16]</xref></p>
        <p>Since propranolol is metabolized by hepatic enzymes and excreted through the renal system, prescribers should proceed with caution when prescribing it to a patient with known hepatic or renal impairments. Furthermore, dosages may need to be adjusted to avoid toxicity resulting from the inability to metabolize or clear the medication from the body properly.</p>
      </sec>
      <sec id="article-27818.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Whenever a patient receives propranolol therapy, it is beneficial to routinely monitor their blood pressure, pulse, and respiratory rate. It is especially important in those with coronary artery disease, COPD, or any other condition that beta-blockade might negatively affect. Regular monitoring is possible at home with portable blood pressure and pulse monitors or routinely scheduled visits to primary care physicians. Physicians should also adjust doses as needed to achieve desired therapeutical outcomes.<xref ref-type="bibr" rid="article-27818.r17">[17]</xref></p>
        <p>Patients receiving propranolol therapy parenterally for conditions such as thyroid storm will need continuous cardiac monitoring in the inpatient setting, typically achieved with the patient connected to constant cardiac monitoring devices.&#x000a0;</p>
      </sec>
      <sec id="article-27818.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Ingestion of greater than 1 g of propranolol in 24 hours can potentially be lethal&#x000a0;and lead to profound bradycardia, bradyarrhythmia, hypotension, bronchospasm.</p>
        <p>When suspecting a beta-blocker overdose, a patient should always receive glucagon immediately. Glucagon has shown to be very effective in reversing beta-blocker overdose, increasing heart rate, and myocardial contractility.<xref ref-type="bibr" rid="article-27818.r18">[18]</xref></p>
      </sec>
      <sec id="article-27818.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The interprofessional healthcare team includes the patient, the physician, the nurse, certified nurse's aid, and the pharmacist, all working in concert to optimize the patient's health. Therefore, all team members must&#x000a0;remain up to date with literature on medication and potential side effects. Furthermore, they must utilize excellent communication skills between the different disciplines to ensure the desired outcome for their patient. A proper history and continuous physical assessments will need to be performed by the health care team to ensure that propranolol is used correctly, with appropriate precautions maintained in at-risk populations to minimize adverse outcomes. Nurses can offer counsel to the patients on their dosing regimen. The pharmacist can check for potential interactions, reinforce the nurse's counsel, answer patient questions, and report any concerns to the prescriber. This interprofessional approach will yield better therapeutic outcomes when using propranolol. [Level 5]</p>
      </sec>
      <sec id="article-27818.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27818&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27818">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27818/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27818">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27818.s11">
        <title>References</title>
        <ref id="article-27818.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalam</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Rasool</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review.</article-title>
            <source>Curr Drug Metab</source>
            <year>2020</year>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-105</page-range>
            <pub-id pub-id-type="pmid">32286940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srinivasan</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Propranolol: A 50-Year Historical Perspective.</article-title>
            <source>Ann Indian Acad Neurol</source>
            <year>2019</year>
            <season>Jan-Mar</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-26</page-range>
            <pub-id pub-id-type="pmid">30692755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000e9;zsi</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Szentes</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The Real Role of &#x003b2;-Blockers in Daily Cardiovascular Therapy.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>361</fpage>
            <page-range>361-373</page-range>
            <pub-id pub-id-type="pmid">28357786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <chapter-title>Propranolol</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">31643543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chamlin</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Frieden</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Frommelt</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Garzon</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>MacLellan-Tobert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Seefeldt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sidbury</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Drolet</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Boucek</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Propranolol treatment of infantile hemangiomas: anticipatory guidance for parents and caretakers.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>155</fpage>
            <page-range>155-9</page-range>
            <pub-id pub-id-type="pmid">23316721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steenen</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>van Wijk</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van der Heijden</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>van Westrhenen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Lange</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Jongh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis.</article-title>
            <source>J Psychopharmacol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-39</page-range>
            <pub-id pub-id-type="pmid">26487439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rehsia</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Dhalla</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure.</article-title>
            <source>Exp Clin Cardiol</source>
            <year>2010</year>
            <season>Winter</season>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>e86</fpage>
            <page-range>e86-95</page-range>
            <pub-id pub-id-type="pmid">21264074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Mistry</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kahlig</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kearney</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Propranolol blocks cardiac and neuronal voltage-gated sodium channels.</article-title>
            <source>Front Pharmacol</source>
            <year>2010</year>
            <volume>1</volume>
            <fpage>144</fpage>
            <pub-id pub-id-type="pmid">21833183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nodari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dei Cas</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Beta-blockade in heart failure: selective versus nonselective agents.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2001</year>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-14</page-range>
            <pub-id pub-id-type="pmid">14728047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenetics of beta-blockers.</article-title>
            <source>Pharmacotherapy</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>874</fpage>
            <page-range>874-87</page-range>
            <pub-id pub-id-type="pmid">17542770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ripley</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>&#x003b2;-blockers: a review of their pharmacological and physiological diversity in hypertension.</article-title>
            <source>Ann Pharmacother</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>723</fpage>
            <page-range>723-33</page-range>
            <pub-id pub-id-type="pmid">24687542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Farzam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Beta Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">30422501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ji</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management.</article-title>
            <source>Sci Rep</source>
            <year>2018</year>
            <month>Mar</month>
            <day>09</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>4264</fpage>
            <pub-id pub-id-type="pmid">29523832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pozzi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[True and presumed contraindications of beta blockers. Peripheral vascular disease, diabetes mellitus, chronic bronchopneumopathy].</article-title>
            <source>Ital Heart J Suppl</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>1</volume>
            <issue>8</issue>
            <fpage>1031</fpage>
            <page-range>1031-7</page-range>
            <pub-id pub-id-type="pmid">10993010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tucker</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Sankar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Theetha Kariyanna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Selective Beta-1 Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29763157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fairbairn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Best evidence topic report. Beta-Blockers in cocaine induced acute coronary syndrome.</article-title>
            <source>Emerg Med J</source>
            <year>2006</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>401</fpage>
            <page-range>401-2</page-range>
            <pub-id pub-id-type="pmid">16627850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akbar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alorainy</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>The current status of beta blockers' use in the management of hypertension.</article-title>
            <source>Saudi Med J</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>11</issue>
            <fpage>1307</fpage>
            <page-range>1307-17</page-range>
            <pub-id pub-id-type="pmid">25399206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27818.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peterson</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Leeder</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Sterner</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Glucagon therapy for beta-blocker overdose.</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1984</year>
            <month>May</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>394</fpage>
            <page-range>394-8</page-range>
            <pub-id pub-id-type="pmid">6144498</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
